NanoViricides Pursues Orphan Drug Designation for Measles Treatment

NanoViricides, Inc. announced the submission of an Orphan Drug Designation (ODD) application for NV-387 to the US FDA Office of Orphan Products Development. NV-387 is designed to treat measles, leveraging NanoViricides' nanomedicine technology. If approved, the designation would offer benefits like tax credits, fee exemptions, and potential market exclusivity for seven years.

Anil R. Diwan, PhD, emphasized the importance of NV-387 as an effective tool against measles, particularly amid rising cases in the USA. In 2025, 2,251 cases and three deaths were recorded, increasing from 59 and 285 cases in the previous years, respectively. The lack of approved treatments for measles underscores the potential impact of NV-387.

NanoViricides collaborated with Only Orphans Cote, LLC, for the ODD application. With global measles resurgence, NV-387 could significantly influence public health by eliminating the need for quarantines and supporting economic stability.